Real-world effectiveness and safety of hyperthermic intraperitoneal chemotherapy and intraperitoneal chemotherapy in ovarian cancer
Real-world-Wirksamkeit und Sicherheit von hyperthermer intraperitonealer Chemotherapie und intraperitonealer Chemotherapie bei Ovarialkarzinom
The Oncologist · 17.01.2026 · 31 (2)
DOI: 10.1093/oncolo/oyaf424 ↗Auf einen Blick
In einer retrospektiven Real-world-Studie mit 606 Patient:innen mit Ovarialkarzinom zeigte HIPEC gegenüber konventioneller intraperitonealer Chemotherapie keinen signifikanten Vorteil beim Überleben. In Subgruppen ergab sich ein Trend zugunsten von HIPEC.
Fragestellung
Vergleicht HIPEC mit konventioneller intraperitonealer Chemotherapie Wirksamkeit und Sicherheit bei Ovarialkarzinom?
Methode
Retrospektive Real-world-Studie mit Inverse-Probability-of-Treatment-Weighting; 606 Patient:innen mit Stadium II-IV nach zytoreduktiver Operation, Behandlung 2013 bis 2024.
Ergebnisse
Nach median 26 Monaten Follow-up trat Progression bei 40,6 % unter HIPEC und 55,0 % unter IP auf (HR 0,79; P = .103). Mortalität: 13,2 % vs. 22,5 % (HR 0,83; P = .434).
Schlussfolgerung der Autor:innen
HIPEC verbesserte im Gesamtkollektiv das Überleben gegenüber konventioneller IP nicht signifikant, zeigte aber einen größeren Nutzen in spezifischen Subgruppen.
Kernaussagen
- Keine signifikanten Unterschiede bei Progression und Überleben im Gesamtkollektiv
- Subgruppen: Trend zugunsten von HIPEC bei BRCA-Wildtyp oder BRCA1-Mutation
- Hypoalbuminämie war das häufigste unerwünschte Ereignis in beiden Gruppen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 19.12.2025. Verfasst von Siyi Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, People's Republic of China. Hauptthemen laut MEDLINE: Hyperthermic Intraperitoneal Chemotherapy, Ovarian Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Basic Research Program of Shaanxi.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Both hyperthermic intraperitoneal chemotherapy (HIPEC) and conventional intraperitoneal chemotherapy (IP) have shown survival benefits in ovarian cancer (OC), but direct comparisons between the two perfusion modalities are lacking. This study aimed to compare effectiveness and safety between HIPEC and conventional IP in OC.
Methods
This retrospective real-world study analyzed 606 patients with stages II-IV OC who received HIPEC or IP following cytoreductive surgery between 2013 and 2024. The primary endpoint was progression-free survival. Overall survival and adverse events were secondary endpoints. The study used inverse probability of treatment propensity-score weighting. We also conducted sensitivity analyses to evaluate result robustness and subgroup analyses to explore potential effect modification.
Results
After a median follow-up of 26 months, disease progression occurred in 40.6% of patients in the HIPEC group and 55.0% in the IP group (hazard ratio [HR] 0.79; P = .103). Mortality rates were 13.2% and 22.5%, respectively (HR 0.83; P = .434), showing no significant differences in progression and survival between the two groups. Exploratory subgroup analyses suggested a trend toward improved progression-free outcomes with HIPEC, particularly among patients with BRCA wild-type or BRCA1-mutated tumors and early postoperative perfusion. Hypoalbuminemia was the most common event in both groups (HIPEC 27.2%; IP 15.6%). HIPEC group had more abdominal distension and wound dehiscence, whereas IP patients experienced nausea and rash more frequently.
Conclusions
HIPEC did not significantly improve survival over conventional IP in the overall population, but showed greater benefit in specific subgroups, underscoring the importance of individualized intraperitoneal chemotherapy strategies in OC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, People's Republic of China.
- Department of Pathology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, People's Republic of China.
- Department of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an 710061, People's Republic of China.
Förderung
- Natural Science Basic Research Program of Shaanxi
Zitieren
APA
Zhang, S., Qie, Q., Zhang, Y., Liang, Y., Yang, S., Wang, Y., Wang, Y., Zhou, Y., Singh, A., Zhao, Y., & Li, Q. (2026). Real-world effectiveness and safety of hyperthermic intraperitoneal chemotherapy and intraperitoneal chemotherapy in ovarian cancer. The Oncologist, 31(2). https://doi.org/10.1093/oncolo/oyaf424
Vancouver
Zhang S, Qie Q, Zhang Y, Liang Y, Yang S, Wang Y, et al. Real-world effectiveness and safety of hyperthermic intraperitoneal chemotherapy and intraperitoneal chemotherapy in ovarian cancer. The Oncologist. 2026;31(2). doi:10.1093/oncolo/oyaf424
BibTeX
@article{Zhang2026,
author = {Zhang, Siyi and Qie, Qian and Zhang, Yuan and Liang, Ye and Yang, Siyu and Wang, Yiran and Wang, Yuqi and Zhou, Yuanyuan and Singh, Aparna and Zhao, Yaling and Li, Qiling},
title = {Real-world effectiveness and safety of hyperthermic intraperitoneal chemotherapy and intraperitoneal chemotherapy in ovarian cancer},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {2},
doi = {10.1093/oncolo/oyaf424}
}
EUVIMED